References
- Kröger N. Approaches to relapse after allogeneic stem cell transplantation. Curr Opin Oncol 2011; 23:203 - 8; http://dx.doi.org/10.1097/CCO.0b013e328342c6c8; PMID: 21157340
- Kim SJ, Nakayama S, Shimazu K, Tamaki Y, Akazawa K, Tsukamoto F, et al. Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers. Ann Oncol 2012; 23:891 - 7; http://dx.doi.org/10.1093/annonc/mdr340; PMID: 21821547
- Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer 2012; 106:133 - 40; http://dx.doi.org/10.1038/bjc.2011.504; PMID: 22108518
- Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153 - 66; http://dx.doi.org/10.1038/nrc2602; PMID: 19238148
- McGowan CH, Russell P. Cell cycle regulation of human WEE1. EMBO J 1995; 14:2166 - 75; PMID: 7774574
- Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer 2007; 7:495 - 507; http://dx.doi.org/10.1038/nrc2169; PMID: 17568790
- Hedblom A, Laursen KB, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A, et al. CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle 2013; 12:1251 - 66; http://dx.doi.org/10.4161/cc.24313; PMID: 23518499